Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of OBT076 in Advanced Solid Tumors
NCT04064359Phase 1Recruiting
- Sponsor
- Oxford BioTherapeutics
- Start
- Jul 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of OBT076 in solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by Oxford BioTherapeutics. Primary endpoints: Incidence of Adverse Events at 1 year and Percentage of subjects with dose-limiting toxicities at 1 year. Started Jul 2019; status: recruiting.
02
Drugs
OBT076
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04064359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064359.